AAPL295.18+5.82 (+2.01%) ▲|ABBV249.56-2.08 (-0.83%) ▼|ABT92.85+2.11 (+2.33%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE212.61+7.59 (+3.70%) ▲|AMAT663.31-59.69 (-8.26%) ▼|AMD551.15-29.77 (-5.12%) ▼|AMGN360.80-1.32 (-0.36%) ▼|AMT165.55+1.98 (+1.21%) ▲|AMZN241.81+3.47 (+1.46%) ▲|AVGO370.59-7.16 (-1.90%) ▼|AXP348.72+10.47 (+3.10%) ▲|BA217.87+1.40 (+0.65%) ▲|BAC58.23+1.25 (+2.19%) ▲|BKNG184.71+6.47 (+3.63%) ▲|BLK978.17+16.61 (+1.73%) ▲|BMY56.66-0.97 (-1.67%) ▼|BNY146.74+2.13 (+1.47%) ▲|BRK-B503.15+2.76 (+0.55%) ▲|C140.73+0.77 (+0.55%) ▲|CAT1,019.34-45.56 (-4.28%) ▼|CL92.49+0.81 (+0.88%) ▲|CMCSA24.16-0.39 (-1.59%) ▼|COF204.94+4.32 (+2.15%) ▲|COP103.74-0.22 (-0.21%) ▼|COST926.70-8.77 (-0.94%) ▼|CRM164.94+8.28 (+5.28%) ▲|CSCO116.33-1.13 (-0.96%) ▼|CVS104.11+0.66 (+0.63%) ▲|CVX166.32+0.56 (+0.34%) ▲|DE631.49-2.84 (-0.45%) ▼|DHR194.76+4.28 (+2.24%) ▲|DIS97.04+0.79 (+0.82%) ▲|DUK126.18-0.40 (-0.32%) ▼|EMR142.47-0.68 (-0.48%) ▼|FDX315.03+1.90 (+0.61%) ▲|GD364.11+9.87 (+2.79%) ▲|GE375.80+2.07 (+0.55%) ▲|GEV1,153.80-21.06 (-1.79%) ▼|GILD126.20-0.15 (-0.11%) ▼|GM76.53-0.56 (-0.72%) ▼|GOOG356.33+3.00 (+0.85%) ▲|GOOGL359.45+2.08 (+0.58%) ▲|GS1,024.23+12.86 (+1.27%) ▲|HD356.34+3.66 (+1.04%) ▲|HON224.19+0.29 (+0.13%) ▲|IBM293.10+11.89 (+4.23%) ▲|INTC129.30-10.33 (-7.40%) ▼|INTU272.00+11.00 (+4.21%) ▲|ISRG404.99+7.31 (+1.84%) ▲|JNJ252.34-1.63 (-0.64%) ▼|JPM334.34+7.01 (+2.14%) ▲|KO81.76+0.49 (+0.60%) ▲|LIN536.04+17.10 (+3.30%) ▲|LLY1,191.20-8.24 (-0.69%) ▼|LMT521.48+12.02 (+2.36%) ▲|LOW225.28+4.79 (+2.17%) ▲|LRCX396.34-36.99 (-8.54%) ▼|MA528.55+14.95 (+2.91%) ▲|MCD270.44+0.13 (+0.05%) ▲|MDLZ59.17+1.33 (+2.29%) ▲|MDT79.40+1.17 (+1.50%) ▲|META618.43+55.14 (+9.79%) ▲|MMM161.68-0.23 (-0.14%) ▼|MO71.96+0.01 (+0.01%) ▲|MRK126.59-1.91 (-1.49%) ▼|MS211.51+2.47 (+1.18%) ▲|MSFT384.67+11.65 (+3.12%) ▲|MU1,053.73-100.57 (-8.71%) ▼|NEE86.95-0.82 (-0.93%) ▼|NFLX73.39+1.99 (+2.78%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.65+6.37 (+6.42%) ▲|NVDA196.89-3.20 (-1.60%) ▼|ORCL145.11-1.44 (-0.98%) ▼|PEP140.05+4.65 (+3.43%) ▲|PFE23.94-0.15 (-0.60%) ▼|PG146.37-0.27 (-0.18%) ▼|PLTR127.19+10.52 (+9.02%) ▲|PM178.43-2.48 (-1.37%) ▼|QCOM185.52+0.73 (+0.39%) ▲|RTX191.39+1.66 (+0.87%) ▲|SBUX101.57-0.63 (-0.61%) ▼|SCHW94.40+2.13 (+2.31%) ▲|SO95.79+0.08 (+0.08%) ▲|SPG221.82-1.84 (-0.82%) ▼|T20.64-0.06 (-0.29%) ▼|TMO520.60+19.24 (+3.84%) ▲|TMUS172.53+4.80 (+2.86%) ▲|TSLA429.34+8.74 (+2.08%) ▲|TXN299.13+1.06 (+0.36%) ▲|UBER73.35+1.19 (+1.65%) ▲|UNH421.65+6.02 (+1.45%) ▲|UNP276.15+4.15 (+1.53%) ▲|UPS109.83+2.33 (+2.17%) ▲|USB61.98+1.58 (+2.62%) ▲|V352.39+9.30 (+2.71%) ▲|VZ42.08-0.27 (-0.63%) ▼|WFC85.52+2.88 (+3.49%) ▲|WMT108.05-5.21 (-4.60%) ▼|XOM136.85+0.13 (+0.10%) ▲|AAPL295.18+5.82 (+2.01%) ▲|ABBV249.56-2.08 (-0.83%) ▼|ABT92.85+2.11 (+2.33%) ▲|ACN131.13+6.69 (+5.38%) ▲|ADBE212.61+7.59 (+3.70%) ▲|AMAT663.31-59.69 (-8.26%) ▼|AMD551.15-29.77 (-5.12%) ▼|AMGN360.80-1.32 (-0.36%) ▼|AMT165.55+1.98 (+1.21%) ▲|AMZN241.81+3.47 (+1.46%) ▲|AVGO370.59-7.16 (-1.90%) ▼|AXP348.72+10.47 (+3.10%) ▲|BA217.87+1.40 (+0.65%) ▲|BAC58.23+1.25 (+2.19%) ▲|BKNG184.71+6.47 (+3.63%) ▲|BLK978.17+16.61 (+1.73%) ▲|BMY56.66-0.97 (-1.67%) ▼|BNY146.74+2.13 (+1.47%) ▲|BRK-B503.15+2.76 (+0.55%) ▲|C140.73+0.77 (+0.55%) ▲|CAT1,019.34-45.56 (-4.28%) ▼|CL92.49+0.81 (+0.88%) ▲|CMCSA24.16-0.39 (-1.59%) ▼|COF204.94+4.32 (+2.15%) ▲|COP103.74-0.22 (-0.21%) ▼|COST926.70-8.77 (-0.94%) ▼|CRM164.94+8.28 (+5.28%) ▲|CSCO116.33-1.13 (-0.96%) ▼|CVS104.11+0.66 (+0.63%) ▲|CVX166.32+0.56 (+0.34%) ▲|DE631.49-2.84 (-0.45%) ▼|DHR194.76+4.28 (+2.24%) ▲|DIS97.04+0.79 (+0.82%) ▲|DUK126.18-0.40 (-0.32%) ▼|EMR142.47-0.68 (-0.48%) ▼|FDX315.03+1.90 (+0.61%) ▲|GD364.11+9.87 (+2.79%) ▲|GE375.80+2.07 (+0.55%) ▲|GEV1,153.80-21.06 (-1.79%) ▼|GILD126.20-0.15 (-0.11%) ▼|GM76.53-0.56 (-0.72%) ▼|GOOG356.33+3.00 (+0.85%) ▲|GOOGL359.45+2.08 (+0.58%) ▲|GS1,024.23+12.86 (+1.27%) ▲|HD356.34+3.66 (+1.04%) ▲|HON224.19+0.29 (+0.13%) ▲|IBM293.10+11.89 (+4.23%) ▲|INTC129.30-10.33 (-7.40%) ▼|INTU272.00+11.00 (+4.21%) ▲|ISRG404.99+7.31 (+1.84%) ▲|JNJ252.34-1.63 (-0.64%) ▼|JPM334.34+7.01 (+2.14%) ▲|KO81.76+0.49 (+0.60%) ▲|LIN536.04+17.10 (+3.30%) ▲|LLY1,191.20-8.24 (-0.69%) ▼|LMT521.48+12.02 (+2.36%) ▲|LOW225.28+4.79 (+2.17%) ▲|LRCX396.34-36.99 (-8.54%) ▼|MA528.55+14.95 (+2.91%) ▲|MCD270.44+0.13 (+0.05%) ▲|MDLZ59.17+1.33 (+2.29%) ▲|MDT79.40+1.17 (+1.50%) ▲|META618.43+55.14 (+9.79%) ▲|MMM161.68-0.23 (-0.14%) ▼|MO71.96+0.01 (+0.01%) ▲|MRK126.59-1.91 (-1.49%) ▼|MS211.51+2.47 (+1.18%) ▲|MSFT384.67+11.65 (+3.12%) ▲|MU1,053.73-100.57 (-8.71%) ▼|NEE86.95-0.82 (-0.93%) ▼|NFLX73.39+1.99 (+2.78%) ▲|NKE43.06+2.01 (+4.90%) ▲|NOW105.65+6.37 (+6.42%) ▲|NVDA196.89-3.20 (-1.60%) ▼|ORCL145.11-1.44 (-0.98%) ▼|PEP140.05+4.65 (+3.43%) ▲|PFE23.94-0.15 (-0.60%) ▼|PG146.37-0.27 (-0.18%) ▼|PLTR127.19+10.52 (+9.02%) ▲|PM178.43-2.48 (-1.37%) ▼|QCOM185.52+0.73 (+0.39%) ▲|RTX191.39+1.66 (+0.87%) ▲|SBUX101.57-0.63 (-0.61%) ▼|SCHW94.40+2.13 (+2.31%) ▲|SO95.79+0.08 (+0.08%) ▲|SPG221.82-1.84 (-0.82%) ▼|T20.64-0.06 (-0.29%) ▼|TMO520.60+19.24 (+3.84%) ▲|TMUS172.53+4.80 (+2.86%) ▲|TSLA429.34+8.74 (+2.08%) ▲|TXN299.13+1.06 (+0.36%) ▲|UBER73.35+1.19 (+1.65%) ▲|UNH421.65+6.02 (+1.45%) ▲|UNP276.15+4.15 (+1.53%) ▲|UPS109.83+2.33 (+2.17%) ▲|USB61.98+1.58 (+2.62%) ▲|V352.39+9.30 (+2.71%) ▲|VZ42.08-0.27 (-0.63%) ▼|WFC85.52+2.88 (+3.49%) ▲|WMT108.05-5.21 (-4.60%) ▼|XOM136.85+0.13 (+0.10%) ▲|
29 C
New York
Wednesday, July 1, 2026

Tag: patients

newssourceFORcompanyinformationcontent1releasesmarket

Pomerantz Law Firm Announces the Filing of a Class Action Against Fortrea Holdings, Inc. and Certain Officers – FTRE

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Fortrea Holdings, Inc. ("Fortrea" or the...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. – PTCT

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT).  Such...

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published...

Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without diabetes.1 REDEFINE 1 met its co-primary endpoints and achieved statistically significant and clinically meaningful weight loss at 68 weeks in patients taking CagriSema versus placebo.1 These data, along with the related phase 3 REDEFINE 2 study conducted in adults with overweight or obesity and type 2 diabetes, were presented today during a scientific symposium at the American Diabetes Association’s (ADA) 85th Scientific Sessions and published in NEJM.

CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM

Data presented simultaneously at the American Diabetes Association's® 85th Scientific Sessions, showed mean weight reduction in the highest range of efficacy observed with existing...

CagriSema Demonstrates Significant Weight Loss in Adults with Obesity

Once-weekly medication results in weight loss of up to 22.7% in adults without diabetes and 15.7% in those with type 2 diabetes CHICAGO, June 22,...

The American Diabetes Association Announces Winners of the Innovation Challenge to Transform Diabetes Care

This challenge Kickstarts additional investments through the new ADA Innovation Fund CHICAGO, June 21, 2025 /PRNewswire/ -- As the American Diabetes Association® (ADA) celebrates its...

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy

Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes

Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular...

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

Abvance presents first-in-human data on insulin-glucagon co-dosing in T1D, demonstrating a novel approach to help prevent hypoglycemia

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers